TBC1D3K
gene geneOn this page
Summary
TBC1D3K (TBC1 domain family member 3K, HGNC:51245) is a protein-coding gene on chromosome 17q12, encoding TBC1 domain family member 3K (A0A087X1G2). Acts as a GTPase activating protein for RAB5.
Predicted to enable GTPase activator activity. Predicted to be located in plasma membrane.
Source: NCBI Gene 101060351 — RefSeq curated summary.
At a glance
- MANE Select transcript:
NM_001291464
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:51245 |
| Approved symbol | TBC1D3K |
| Name | TBC1 domain family member 3K |
| Location | 17q12 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000273513 |
| Ensembl biotype | protein_coding |
| Entrez | 101060351 |
Gene structure
Transcript identifiers
Ensembl transcripts: 2 — 2 protein_coding
ENST00000620247, ENST00000859823
RefSeq mRNA: 1 — MANE Select: NM_001291464
NM_001291464
CCDS: CCDS74042
Canonical transcript exons
ENST00000620247 — 14 exons
| Exon | Start | End |
|---|---|---|
| ENSE00003714746 | 37925999 | 37926071 |
| ENSE00003718862 | 37932355 | 37932420 |
| ENSE00003721162 | 37933354 | 37933506 |
| ENSE00003721663 | 37930450 | 37930498 |
| ENSE00003725945 | 37929086 | 37929195 |
| ENSE00003727598 | 37928649 | 37928756 |
| ENSE00003729342 | 37928125 | 37928205 |
| ENSE00003732792 | 37932884 | 37932983 |
| ENSE00003736059 | 37924415 | 37924570 |
| ENSE00003738981 | 37931042 | 37931162 |
| ENSE00003739666 | 37931876 | 37931970 |
| ENSE00003746506 | 37927603 | 37927642 |
| ENSE00003751653 | 37926234 | 37926319 |
| ENSE00003978224 | 37934488 | 37935371 |
Expression profiles
Bgee: expression breadth ubiquitous, 102 present calls, max score 98.02.
Top tissues by expression
133 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 98.02 | gold quality |
| bone marrow cell | CL:0002092 | 54.92 | silver quality |
| bone marrow | UBERON:0002371 | 46.13 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 44.16 | gold quality |
| muscle tissue | UBERON:0002385 | 42.26 | gold quality |
| right uterine tube | UBERON:0001302 | 42.19 | silver quality |
| duodenum | UBERON:0002114 | 42.03 | gold quality |
| lymph node | UBERON:0000029 | 40.94 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 39.32 | gold quality |
| blood | UBERON:0000178 | 38.70 | gold quality |
| ganglionic eminence | UBERON:0004023 | 37.82 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 37.77 | gold quality |
| colonic epithelium | UBERON:0000397 | 37.20 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| fundus of stomach | UBERON:0001160 | 36.24 | gold quality |
| testis | UBERON:0000473 | 34.54 | gold quality |
| cortex of kidney | UBERON:0001225 | 34.52 | gold quality |
| right testis | UBERON:0004534 | 34.39 | gold quality |
| right coronary artery | UBERON:0001625 | 34.35 | gold quality |
| left testis | UBERON:0004533 | 33.43 | gold quality |
| tonsil | UBERON:0002372 | 33.32 | gold quality |
| metanephros cortex | UBERON:0010533 | 32.88 | gold quality |
| kidney | UBERON:0002113 | 32.40 | gold quality |
| liver | UBERON:0002107 | 32.34 | gold quality |
| adult mammalian kidney | UBERON:0000082 | 32.05 | gold quality |
| muscle of leg | UBERON:0001383 | 31.57 | gold quality |
| primary visual cortex | UBERON:0002436 | 31.16 | gold quality |
| sural nerve | UBERON:0015488 | 30.93 | gold quality |
| gastrocnemius | UBERON:0001388 | 30.62 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.32 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
19 targeting TBC1D3K, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-1250-3P | 99.96 | 70.04 | 4038 |
| HSA-MIR-335-3P | 99.93 | 73.36 | 4958 |
| HSA-MIR-4731-5P | 99.89 | 67.23 | 2537 |
| HSA-MIR-4492 | 99.87 | 68.25 | 3611 |
| HSA-MIR-130B-5P | 99.83 | 68.50 | 1888 |
| HSA-MIR-374C-5P | 99.80 | 72.06 | 2910 |
| HSA-MIR-655-3P | 99.80 | 72.19 | 2909 |
| HSA-MIR-7110-5P | 99.80 | 67.84 | 1712 |
| HSA-MIR-12130 | 99.75 | 65.47 | 452 |
| HSA-MIR-5584-5P | 99.49 | 68.22 | 2814 |
| HSA-MIR-4505 | 99.27 | 67.81 | 2678 |
| HSA-MIR-3940-5P | 99.14 | 65.26 | 493 |
| HSA-MIR-4507 | 99.14 | 65.27 | 515 |
| HSA-MIR-421 | 98.90 | 67.04 | 1883 |
| HSA-MIR-7155-5P | 98.65 | 66.14 | 1290 |
| HSA-MIR-8060 | 98.61 | 66.93 | 1187 |
| HSA-MIR-5585-5P | 97.95 | 68.80 | 1024 |
| HSA-MIR-3135A | 96.41 | 65.30 | 494 |
| HSA-MIR-548AD-3P | 94.39 | 66.04 | 350 |
Cross-species orthologs
0 orthologs
Paralogs (45): RABGAP1 (ENSG00000011454), TBC1D22A (ENSG00000054611), TBC1D22B (ENSG00000065491), TBC1D1 (ENSG00000065882), EVI5 (ENSG00000067208), TBC1D25 (ENSG00000068354), TBC1D2 (ENSG00000095383), TBC1D10A (ENSG00000099992), SGSM3 (ENSG00000100359), TBC1D17 (ENSG00000104946), TBC1D13 (ENSG00000107021), TBC1D12 (ENSG00000108239), TBC1D9 (ENSG00000109436), TBC1D30 (ENSG00000111490), TBC1D15 (ENSG00000121749), TBC1D5 (ENSG00000131374), TBC1D14 (ENSG00000132405), TBC1D8B (ENSG00000133138), TBC1D4 (ENSG00000136111), GRTP1 (ENSG00000139835), SGSM2 (ENSG00000141258), EVI5L (ENSG00000142459), TBCK (ENSG00000145348), USP6NL (ENSG00000148429), RABGAP1L (ENSG00000152061), SGSM1 (ENSG00000167037), TBC1D21 (ENSG00000167139), TBC1D2B (ENSG00000167202), TBC1D16 (ENSG00000167291), TBC1D10B (ENSG00000169221), TBC1D10C (ENSG00000175463), TBC1D28 (ENSG00000189375), TBC1D9B (ENSG00000197226), TBC1D8 (ENSG00000204634), TBC1D26 (ENSG00000214946), TBC1D3G (ENSG00000260287), TBC1D3H (ENSG00000274226), TBC1D3D (ENSG00000274419), TBC1D3L (ENSG00000274512), TBC1D3 (ENSG00000274611)
Protein
Protein identifiers
TBC1 domain family member 3K — A0A087X1G2 (reviewed: A0A087X1G2)
All UniProt accessions (1): A0A087X1G2
UniProt curated annotations — full annotation on UniProt →
Function. Acts as a GTPase activating protein for RAB5. Does not act on RAB4 or RAB11.
Subcellular location. Cell membrane.
Post-translational modifications. Ubiquitinated by a CUL7-based E3 ligase, which leads to proteasomal degradation. Palmitoylation is required for membrane localization and protects TBC1D3 from ubiquitination.
Miscellaneous. TBC1D3 is encoded by a collection of very similar paralogs with multiple copies of each paralog, some human genomes encoding well over 50 copies depending on ethnic origin of the donor.
RefSeq proteins (1): NP_001278393* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000195 | Rab-GAP-TBC_dom | Domain |
| IPR035969 | Rab-GAP_TBC_sf | Homologous_superfamily |
| IPR050302 | Rab_GAP_TBC_domain | Family |
Pfam: PF00566
UniProt features (6 total): lipid moiety-binding region 2, chain 1, domain 1, region of interest 1, compositionally biased region 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-A0A087X1G2-F1 | 60.96 | 0.25 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (2): 318, 325
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 11 (showing top):
GOMF_ENZYME_ACTIVATOR_ACTIVITY, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, MIR335_3P, MIR5585_5P, chr17q12, JINESH_BLEBBISHIELD_VS_LIVE_CONTROL_UP, GOMF_MOLECULAR_FUNCTION_ACTIVATOR_ACTIVITY, WP_17Q12_COPY_NUMBER_VARIATION_SYNDROME, GOCC_ENDOSOME, GOMF_GTPASE_ACTIVATOR_ACTIVITY
GO Biological Process (0):
GO Molecular Function (1): GTPase activator activity (GO:0005096)
GO Cellular Component (3): endosome (GO:0005768), plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| GTPase activity | 1 |
| enzyme activator activity | 1 |
| GTPase regulator activity | 1 |
| endomembrane system | 1 |
| cytoplasmic vesicle | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
134 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TBC1D3K | KRTAP2-2 | Q9BYT5 | 590 |
| TBC1D3K | ERLN | P0DI80 | 571 |
| TBC1D3K | C17orf50 | Q8WW18 | 570 |
| TBC1D3K | SCGB1C2 | P0DMR2 | 542 |
| TBC1D3K | KRTAP9-7 | A8MTY7 | 526 |
| TBC1D3K | CDRT15L2 | A8MXV6 | 506 |
| TBC1D3K | MTRNR2L1 | P0CJ68 | 506 |
| TBC1D3K | CFAP97D1 | B2RV13 | 446 |
| TBC1D3K | SPMAP1 | A8MV24 | 434 |
| TBC1D3K | KRTAP9-8 | Q9BYQ0 | 432 |
| TBC1D3K | SPEM2 | Q0P670 | 419 |
| TBC1D3K | OR1E2 | P47887 | 418 |
| TBC1D3K | CCDC144A | A2RUR9 | 402 |
| TBC1D3K | SLC35G6 | P0C7Q6 | 399 |
| TBC1D3K | SLC35G3 | Q8N808 | 398 |
IntAct
0 interactions, top by confidence:
BioGRID (5): TBC1D3K (Two-hybrid), TBC1D3K (Two-hybrid), TBC1D3K (Negative Genetic), TBC1D3K (Negative Genetic), TBC1D3K (Negative Genetic)
ESM2 similar proteins: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A6NDS4, A6NER0, A6QPT6, B9A6J9, M3WHG5, O14771, O15482, O15553, O19110, O76081, P0C7X1, P0C7X3, P0C7X4, P35125, P48778, P48967, P79209, Q13670, Q15697, Q2TBC4, Q3T191, Q3UZD7, Q4R2Z8, Q5DRQ5, Q5SSQ6, Q5XFX8, Q69ZB3, Q6DHY5, Q6IPX1, Q6ZMN8, Q8BLR5, Q8BWA8, Q8IYF1, Q8IZP1, Q8JZW5, Q8N7G0
Diamond homologs: A0A087WVF3, A0A087WXS9, A0A087X179, A0A087X1G2, A2AWA9, A6H6A9, A6NDS4, A6NER0, B9A6J9, H2KZZ6, P0C7X1, P35125, Q2M2D7, Q5RAN1, Q5SVR0, Q66K14, Q6DHY5, Q6IPX1, Q80XC3, Q86UD7, Q8IZP1, Q92738, Q9UFV1, Q9Y3P9, A3KGB4, A6QP29, B0R0W9, B7ZAP0, O60343, O60447, O95759, O97790, P58802, P97366, Q0IIM8, Q10496, Q12317, Q12344, Q28CB1, Q3UYK3
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
0 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
2467 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 17:37928647:A:AG | acceptor_gain | 1.0000 |
| 17:37928648:G:GA | acceptor_gain | 1.0000 |
| 17:37929196:G:GG | donor_gain | 1.0000 |
| 17:37932979:GCAGA:G | donor_gain | 1.0000 |
| 17:37932982:GA:G | donor_gain | 1.0000 |
| 17:37932982:GAGT:G | donor_loss | 1.0000 |
| 17:37932983:AGTA:A | donor_loss | 1.0000 |
| 17:37932984:G:GG | donor_gain | 1.0000 |
| 17:37932984:GTAA:G | donor_loss | 1.0000 |
| 17:37934487:GCC:G | acceptor_gain | 1.0000 |
| 17:37924570:GGTG:G | donor_loss | 0.9900 |
| 17:37924571:G:C | donor_loss | 0.9900 |
| 17:37926315:GTACA:G | donor_gain | 0.9900 |
| 17:37926320:G:GG | donor_gain | 0.9900 |
| 17:37927601:A:AG | acceptor_gain | 0.9900 |
| 17:37927602:G:GG | acceptor_gain | 0.9900 |
| 17:37928644:CACA:C | acceptor_loss | 0.9900 |
| 17:37928645:ACAGC:A | acceptor_loss | 0.9900 |
| 17:37928646:CAGCT:C | acceptor_loss | 0.9900 |
| 17:37928647:A:AT | acceptor_loss | 0.9900 |
| 17:37928648:GCT:G | acceptor_gain | 0.9900 |
| 17:37928648:GCTC:G | acceptor_gain | 0.9900 |
| 17:37928752:ACCAG:A | donor_loss | 0.9900 |
| 17:37928753:CCAG:C | donor_loss | 0.9900 |
| 17:37928754:CAG:C | donor_loss | 0.9900 |
| 17:37928755:AGGT:A | donor_loss | 0.9900 |
| 17:37928756:GGTA:G | donor_loss | 0.9900 |
| 17:37928757:GT:G | donor_loss | 0.9900 |
| 17:37928758:T:A | donor_loss | 0.9900 |
| 17:37929070:T:TA | acceptor_gain | 0.9900 |
AlphaMissense
3579 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 17:37931114:T:C | F207L | 0.981 |
| 17:37931116:C:A | F207L | 0.981 |
| 17:37931116:C:G | F207L | 0.981 |
| 17:37932911:T:A | W286R | 0.932 |
| 17:37932911:T:C | W286R | 0.932 |
| 17:37928700:T:A | W111R | 0.929 |
| 17:37928700:T:C | W111R | 0.929 |
| 17:37931117:T:A | W208R | 0.901 |
| 17:37931117:T:C | W208R | 0.901 |
| 17:37929094:G:C | K132N | 0.899 |
| 17:37929094:G:T | K132N | 0.899 |
| 17:37931115:T:C | F207S | 0.895 |
| 17:37928158:T:A | W78R | 0.894 |
| 17:37928158:T:C | W78R | 0.894 |
| 17:37928702:G:C | W111C | 0.889 |
| 17:37928702:G:T | W111C | 0.889 |
| 17:37931119:G:C | W208C | 0.888 |
| 17:37931119:G:T | W208C | 0.888 |
| 17:37931111:G:C | A206P | 0.879 |
| 17:37929173:T:C | F159L | 0.877 |
| 17:37929175:C:A | F159L | 0.877 |
| 17:37929175:C:G | F159L | 0.877 |
| 17:37928160:G:C | W78C | 0.869 |
| 17:37928160:G:T | W78C | 0.869 |
| 17:37928752:A:C | Y128S | 0.862 |
| 17:37928157:G:C | K77N | 0.860 |
| 17:37928157:G:T | K77N | 0.860 |
| 17:37928181:G:C | W85C | 0.854 |
| 17:37928181:G:T | W85C | 0.854 |
| 17:37928751:T:G | Y128D | 0.854 |
dbSNP variants (sampled 300 via entrez): RS1157054647 (17:37930915 C>T), RS1157917450 (17:37932837 C>A,T), RS1158264303 (17:37921811 C>A), RS1158392012 (17:37930240 G>T), RS1158401122 (17:37924612 G>A), RS1158497970 (17:37923616 C>G,T), RS1159100165 (17:37930891 T>A,C), RS1159153691 (17:37923200 G>C), RS1159198773 (17:37929448 A>G), RS1159379071 (17:37922397 T>C), RS1160546016 (17:37933463 T>C), RS1161108855 (17:37921640 T>A), RS1161436582 (17:37923291 G>C), RS1162485563 (17:37924358 GA>G), RS1162903966 (17:37929646 A>G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
5 total (human), top 5 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | increases expression | 1 |
| tri-o-cresyl phosphate | increases expression | 1 |
| 2-palmitoylglycerol | increases expression | 1 |
| Smoke | decreases expression | 1 |
| Tretinoin | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.